June 23, 2020
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Chris Edwards and Joe McCann
| Re: | Fusion Pharmaceuticals, Inc. |
Registration Statement on Form S-1
File No. 333-238968
Acceleration Request
Requested Date: June 25, 2020
Requested Time: 4:00 p.m., Eastern Standard Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Morgan Stanley & Co. LLC, Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters, hereby join Fusion Pharmaceuticals Inc. in requesting that the Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-238968) (the “Registration Statement”) to become effective on June 25, 2020, at 4:00 p.m., Eastern Standard Time, or as soon as practicable thereafter.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
[Signature Page Follows]
Very truly yours,
MORGAN STANLEY & CO LLC | ||
| By: | /s/ Kalli Dircks | |
Name: Title: | Kalli Dircks Executive Director | |
| JEFFERIES LLC | ||
| By: | /s/ Matt Kim | |
Name: Title: | Matt Kim Managing Director | |
| COWEN AND COMPANY, LLC | ||
| By: | /s/ Bill Follis | |
Name: Title: | Bill Follis Managing Director | |
| cc: | John Valliant, Ph.D., Fusion Pharmaceuticals, Inc. |
Mitchell S. Bloom, Goodwin Proctor LLP
Seo Salimi, Goodwin Proctor LLP
Peter N. Handrinos, Latham & Watkins LLP
Wesley Holmes, Latham & Watkins LLP
[Signature Page to Acceleration Request]
